Stock listing
NASDAQ:ACAD ACADIA Pharmaceuticals Inc. Stock
Home listing (NASDAQ) of ACADIA Pharmaceuticals Inc.
Follow ACADIA Pharmaceuticals Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ACAD
$17.11 USD -0.72 (-4.0%)
Close on Nov 20, 2026
- Day range
- $17.05 – $17.79 USDNov 20, 2026
- Volume
- 1.90M sharesNov 20, 2026
- Market cap
- $2.96B USDAt the close on Nov 20, 2026 · price × 172.8M shares outstanding
- 52-week range
- $15.86 – $30.96 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $47.08M USDMedian day 1.63M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ACAD · Home | $17.11 USD | -0.72 (-4.0%) | 1,903,306 | $17.47 | $17.79 | $17.05 | $17.83 | Close on Nov 20, 2026 |
| Frankfurt:DR6 | €15.81 EUR | -0.495 (-3.0%) | — | €15.81 | €15.81 | €15.81 | €16.31 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ACAD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $17.11 | -0.72 | -4.0% | $17.47 | $17.79 | $17.05 | 1,903,306 | |
| $17.83 | -0.49 | -2.7% | $18.10 | $18.49 | $17.83 | 1,895,555 | |
| $18.32 | -0.35 | -1.9% | $18.54 | $18.73 | $17.94 | 1,535,421 | |
| $18.67 | -0.08 | -0.4% | $18.84 | $19.44 | $18.59 | 2,116,858 | |
| $18.75 | +0.61 | +3.4% | $18.12 | $18.76 | $18.00 | 1,785,088 | |
| $18.14 | -0.23 | -1.3% | $18.22 | $18.37 | $17.93 | 1,934,198 | |
| $18.37 | +0.09 | +0.5% | $18.13 | $18.58 | $17.90 | 2,395,219 | |
| $18.28 | +1.78 | +10.8% | $16.41 | $18.39 | $16.38 | 6,354,161 | |
| $16.50 | -4.73 | -22.3% | $21.41 | $21.66 | $15.86 | 12,150,930 | |
| $21.23 | -0.01 | 0.0% | $21.00 | $21.45 | $20.59 | 1,770,851 | |
| $21.24 | -0.23 | -1.1% | $21.98 | $22.63 | $21.14 | 6,027,494 | |
| $21.47 | +0.90 | +4.4% | $21.18 | $21.54 | $20.51 | 4,719,961 | |
| $20.57 | +0.10 | +0.5% | $20.50 | $20.82 | $20.45 | 1,709,205 | |
| $20.47 | -0.12 | -0.6% | $20.71 | $20.76 | $20.25 | 1,384,944 | |
| $20.59 | -0.17 | -0.8% | $20.88 | $21.01 | $20.49 | 1,137,497 | |
| $20.76 | +0.44 | +2.2% | $20.61 | $20.88 | $20.50 | 2,193,810 | |
| $20.32 | +0.15 | +0.7% | $20.00 | $20.35 | $20.00 | 1,336,007 | |
| $20.17 | +0.43 | +2.2% | $19.58 | $20.29 | $19.51 | 1,332,125 | |
| $19.74 | +0.01 | +0.1% | $19.72 | $19.89 | $19.59 | 1,229,734 | |
| $19.73 | -0.58 | -2.9% | $20.22 | $20.25 | $19.58 | 1,066,084 | |
| $20.31 | +0.12 | +0.6% | $20.30 | $20.50 | $20.12 | 1,229,385 | |
| $20.19 | -0.25 | -1.2% | $20.44 | $20.57 | $20.10 | 1,409,868 | |
| $20.44 | +0.64 | +3.2% | $20.04 | $20.49 | $19.86 | 1,675,506 | |
| $19.80 | +0.68 | +3.6% | $19.33 | $19.84 | $19.11 | 1,298,632 | |
| $19.12 | -0.59 | -3.0% | $19.76 | $19.76 | $18.87 | 1,672,256 | |
| $19.71 | +0.46 | +2.4% | $19.48 | $19.88 | $19.28 | 1,767,168 | |
| $19.25 | +0.63 | +3.4% | $18.60 | $19.28 | $18.49 | 1,642,771 | |
| $18.62 | -0.79 | -4.1% | $19.05 | $19.10 | $18.39 | 2,140,646 | |
| $19.41 | -0.37 | -1.9% | $19.70 | $19.87 | $19.40 | 1,184,727 | |
| $19.78 | +0.20 | +1.0% | $19.60 | $20.05 | $19.58 | 1,470,247 | |
| $19.58 | -0.07 | -0.4% | $19.46 | $19.79 | $19.32 | 2,006,572 | |
| $19.65 | -0.09 | -0.5% | $19.60 | $19.80 | $19.46 | 1,784,747 | |
| $19.74 | -0.37 | -1.8% | $20.16 | $20.36 | $19.67 | 1,666,303 | |
| $20.11 | +0.16 | +0.8% | $20.05 | $20.45 | $19.57 | 3,152,355 | |
| $19.95 | +0.06 | +0.3% | $20.01 | $20.24 | $19.88 | 2,564,592 | |
| $19.89 | -0.26 | -1.3% | $19.95 | $20.19 | $19.59 | 2,731,696 | |
| $20.15 | -0.07 | -0.3% | $20.28 | $20.70 | $19.93 | 3,134,008 | |
| $20.22 | -0.31 | -1.5% | $20.61 | $20.61 | $20.06 | 2,515,050 | |
| $20.53 | -0.15 | -0.7% | $20.53 | $20.63 | $19.80 | 3,522,828 | |
| $20.68 | -1.50 | -6.8% | $22.21 | $22.21 | $20.61 | 3,364,113 | |
| $22.18 | -3.25 | -12.8% | $24.38 | $24.38 | $21.97 | 6,761,623 | |
| $25.43 | -0.98 | -3.7% | $26.41 | $26.51 | $24.93 | 1,306,066 | |
| $26.41 | +0.015 | +0.1% | $26.65 | $26.86 | $26.32 | 1,472,449 | |
| $26.40 | -0.895 | -3.3% | $27.43 | $27.43 | $26.34 | 1,351,979 | |
| $27.29 | -0.16 | -0.6% | $27.37 | $27.48 | $26.73 | 5,482,812 | |
| $27.45 | -0.09 | -0.3% | $27.78 | $28.06 | $27.29 | 1,307,767 | |
| $27.54 | +0.78 | +2.9% | $26.75 | $27.60 | $26.66 | 1,405,152 | |
| $26.76 | -0.76 | -2.8% | $27.51 | $27.51 | $26.64 | 1,109,419 | |
| $27.52 | -0.31 | -1.1% | $28.00 | $28.10 | $27.38 | 1,628,513 | |
| $27.83 | +0.09 | +0.3% | $27.98 | $28.24 | $27.74 | 1,172,902 | |
| $27.74 | +0.06 | +0.2% | $27.63 | $27.86 | $27.36 | 1,014,565 | |
| $27.68 | +0.10 | +0.4% | $27.44 | $27.95 | $27.40 | 1,293,919 | |
| $27.58 | -0.44 | -1.6% | $27.63 | $28.09 | $27.10 | 1,457,760 | |
| $28.02 | +0.16 | +0.6% | $27.77 | $28.19 | $27.65 | 1,682,950 | |
| $27.86 | -1.07 | -3.7% | $29.00 | $29.07 | $27.62 | 1,849,411 | |
| $28.93 | +0.04 | +0.1% | $29.10 | $29.75 | $28.88 | 1,555,986 | |
| $28.89 | -0.02 | -0.1% | $28.84 | $29.30 | $28.51 | 830,928 | |
| $28.91 | -0.20 | -0.7% | $29.05 | $29.12 | $28.58 | 1,035,961 | |
| $29.11 | -0.62 | -2.1% | $29.51 | $29.73 | $29.02 | 1,529,974 | |
| $29.73 | +0.15 | +0.5% | $29.26 | $29.83 | $29.15 | 879,365 | |
| $29.58 | -0.99 | -3.2% | $30.36 | $30.38 | $29.28 | 1,336,189 | |
| $30.57 | +0.92 | +3.1% | $30.14 | $30.76 | $29.85 | 1,523,784 | |
| $29.65 | +0.15 | +0.5% | $29.50 | $29.78 | $29.15 | 1,489,609 | |
| $29.50 | +0.46 | +1.6% | $29.08 | $29.62 | $28.80 | 1,093,516 | |
| $29.04 | -1.17 | -3.9% | $30.00 | $30.00 | $28.95 | 1,318,712 |
- Ticker
- NASDAQ:ACAD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Latest earnings call · Nov 4, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Q3 2026 Earnings Presentation
Earnings · 25 slides
Latest news
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Nov 17, 2026
Closed $18.32 (-1.9%) on Nov 17, 2026
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
Nov 16, 2026
Closed $18.67 (-0.4%) on Nov 16, 2026
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
Nov 9, 2026
Closed $18.28 (+10.8%) on Nov 10, 2026
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
Nov 9, 2026
Closed $18.28 (+10.8%) on Nov 10, 2026
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Nov 4, 2026
Closed $21.24 (-1.1%) on Nov 5, 2026
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
Oct 28, 2026
Closed $20.76 (+2.2%) on Oct 29, 2026
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Oct 21, 2026
Closed $20.31 (+0.6%) on Oct 22, 2026
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
Sep 28, 2026
Closed $20.22 (-1.5%) on Sep 29, 2026
ACADIA Pharmaceuticals Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 30 in the last 12 months · 200 in all · newest Nov 17, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest Nov 4, 2026
- Decks
- 32 decks · latest Nov 4, 2026
Where ACADIA Pharmaceuticals Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ACAD · Home listing · This page | NASDAQ | United States | USD |
| gettex:DR6 | gettex | Germany | EUR |
| Tradegate:DR6 | Tradegate | Germany | EUR |
| BMV:ACAD | BMV | Mexico | MXN |
| LS Exchange:603035 | LS Exchange | Germany | EUR |
| Lang & Schwarz:603035 | Lang & Schwarz | Germany | EUR |
| Frankfurt:DR6 | Frankfurt | Germany | EUR |
| BIVA:ACAD | BIVA | Mexico | MXN |
| BOATS:ACAD | BOATS | United States | USD |
| LSE:0A4W | LSE | United Kingdom | USD |
| Dusseldorf:DR6 | Dusseldorf | Germany | EUR |
| Munich:DR6 | Munich | Germany | EUR |
| Stuttgart:DR6 | Stuttgart | Germany | EUR |
Valuation
P/E 8.2× against a median of 16.5×: 2nd lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.05B USD
- P/E
- 8.2×
- EV/sales
- 1.7×
- EV/EBITDA
- 15.5×
- Price/book
- 2.1×
- Gross margin
- 90.5%
- Operating margin
- 10.2%
- Net margin
- 30.1%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.40
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc. · NASDAQ:ACAD | US$2.96B | US$2.05B | 8.2× | 1.7× | 15.5× | 2.1× | 30.1% | 0.1× | 0.40 |
| Hualan Biological Engineering Inc. Class A · SZSE:002007 | US$3.13B | US$2.62B | 35.6× | 4.6× | n/a | 2.0× | 15.4% | 0.0× | n/a |
| Xeris Biopharma Holdings, Inc. · NASDAQ:XERS | US$3.10B | US$3.16B | n/a | 8.6× | 58.9× | 63.5× | −1.8% | 3.9× | 0.11 |
| Bausch Health Companies Inc. · TSX:BHC | US$3.08B | US$21.23B | n/a | 1.9× | n/a | n/a | −7.6% | n/a | 0.65 |
| Rubicon Research Limited · NSE:RUBICON | US$3.07B | US$3.05B | 98.7× | 14.6× | 62.8× | 22.1× | 14.9% | 0.1× | n/a |
| Jilin Aodong Pharmaceutical Group Co., Ltd. Class A · SZSE:000623 | US$2.97B | US$2.55B | 6.6× | 7.6× | n/a | 0.6× | 133.7% | 0.0× | n/a |
| ADMA Biologics Inc · NASDAQ:ADMA | US$2.92B | US$2.99B | 16.0× | 5.8× | 12.0× | 6.7× | 35.1% | 0.5× | 0.05 |
| Telix Pharmaceuticals Limited · ASX:TLX | US$2.90B | US$3.22B | n/a | 4.0× | 63.0× | 5.9× | −0.9% | 1.2× | n/a |
| Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A · SZSE:002773 | US$2.89B | US$1.93B | 21.1× | 3.1× | n/a | 2.0× | 22.1% | 0.0× | n/a |
| China Medical System Holdings Ltd. · HKEX:867 | US$2.86B | US$2.14B | 12.8× | 1.7× | 7.7× | 1.1× | 18.1% | 0.1× | n/a |
| Joincare Pharmaceutical Group Industry Co., Ltd. Class A · SSE:600380 | US$2.79B | US$1.15B | 16.5× | 0.6× | n/a | 1.3× | 8.4% | 0.1× | n/a |
| Median of the others | US$2.95B | US$2.81B | 16.5× | 4.3× | 58.9× | 2.0× | 15.2% | 0.1× | 0.11 |
Forecasts
10 strong buy · 4 buy · 5 hold · 1 strong sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 30.32 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.77 · 13 analysts
- Revenue, year to Dec 2026
- 1.28B · 19 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Catherine Owen Adams | Chief Executive Officer |
| Mark Schneyer | Chief Financial Officer |
| Jennifer J. Rhodes | Chief Legal Officer and Secretary |
| Carl Segerstrom | Chief People Officer |
| Konstantina Katcheves | Chief Business and Strategy Officer |
| Scott Cenci | Chief Information and Data Officer |
Board
| Director | Role |
|---|---|
| Stephen Biggar | Chairman |
| Adora Ndu | Director |
| Edmund Harrigan | Director |
| Elizabeth Garofalo | Director |
| James Daly | Director |
| Jonathan M. Poole | Director |
| Julian Baker | Director |
| Laura Brege | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2026 Earnings Call | Tue, Aug 04, 2026 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Call | Wed, May 06, 2026 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q4 2025 Earnings Call | Wed, Feb 25, 2026 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2025 Earnings Call | Wed, May 07, 2025 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q4 2024 Earnings Call | Wed, Feb 26, 2025 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 4:30 PM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −1.1% |
| Q2 2026 | Aug 4, 2026 · After close | +6.1% |
| Q1 2026 | May 6, 2026 · After close | +5.0% |
| Q4 2025 | Mar 2, 2026 | −8.4% |
| Q3 2025 | Nov 5, 2025 · After close | −3.0% |
| Q2 2025 | Aug 6, 2025 · After close | +2.5% |
| Q1 2025 | May 7, 2025 · After close | +14.3% |
| Q4 2024 | Feb 25, 2025 · Before open | −2.4% |
| Q3 2024 | Nov 6, 2024 · After close | +8.9% |
| Q2 2024 | Aug 6, 2024 · After close | −19.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −11.2% |
| Q4 2023 | Feb 27, 2024 · After close | −9.9% |
| Q3 2023 | Nov 2, 2023 · After close | +4.7% |
| Q2 2023 | Aug 2, 2023 · After close | −6.8% |
| Q1 2023 | May 8, 2023 · After close | −0.6% |
| Q4 2022 | Feb 27, 2023 · After close | +6.7% |
| Q3 2022 | Nov 2, 2022 · After close | −7.0% |
| Q2 2022 | Aug 8, 2022 · After close | −2.4% |
| Q1 2022 | May 4, 2022 · After close | −5.3% |
| Q4 2021 | Feb 28, 2022 · After close | −1.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 25 slides | Nov 4, 2026 |
| Technical Presentation (September 2026) | Technical | 19 slides | Sep 24, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 21 slides | Aug 4, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 20 slides | Feb 25, 2026 |
| Clinical Trials on Alzheimer's Disease (CTAD) 2026 | Conference | 14 slides | 2026 |
| Q3 2025 Earnings Presentation | Earnings | 17 slides | Nov 5, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 20 slides | Aug 6, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 19 slides | May 7, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 25 slides | Feb 26, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 22 slides | Nov 6, 2024 |
All 32 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.07B | 957.8M | 726.4M | 517.2M | 484.1M | 441.8M | 339.1M | 223.8M | 124.9M | 17.3M |
| Cost of revenue | 89.0M | 81.8M | 41.6M | 10.2M | 19.1M | 10.2M | 11.3M | 12.4M | 9.08M | 3.08M |
| Gross profit | 982.5M | 876.0M | 684.8M | 507.1M | 473.3M | 431.5M | 327.7M | 211.4M | 115.8M | 14.3M |
| Research and development | 328.8M | 303.2M | 351.6M | 361.6M | 239.4M | 319.1M | 240.4M | 187.2M | 149.2M | 99.3M |
| Selling, general and administrative | 548.9M | 488.4M | 406.6M | 369.1M | 396.0M | 388.7M | 325.6M | 265.8M | 255.1M | 186.5M |
| Operating income | 104.8M | 230.8M | -73.4M | -223.6M | -170.4M | -286.6M | -246.5M | -247.4M | -292.4M | -272.8M |
| Depreciation and amortization | 871.0K | 920.0K | 1.46M | 2.03M | 2.24M | 1.46M | 1.29M | 1.53M | 1.24M | 843.0K |
| EBITDA | 105.7M | 231.7M | -71.9M | -221.6M | -168.2M | -285.1M | -245.3M | -245.9M | -291.2M | -272.0M |
| Interest expense | 6.61M | 6.26M | 8.54M | 14.9M | 0 | 0 | 0 | |||
| Income before tax | 138.9M | 258.1M | -51.0M | -213.4M | -167.5M | -281.0M | -234.4M | -243.9M | -288.3M | -270.1M |
| Income tax | -252.1M | 31.6M | 10.3M | 2.53M | 351.0K | 611.0K | 876.0K | 1.26M | 1.12M | 1.34M |
| Net income | 391.0M | 226.5M | -61.3M | -216.0M | -167.9M | -281.6M | -235.3M | -245.2M | -289.4M | -271.4M |
| Earnings per share, basic | 2.32 | 1.37 | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 |
| Earnings per share, diluted | 2.30 | 1.36 | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 177.7M | 319.6M | 188.7M | 114.8M | 147.4M | 326.0M | 189.7M | 134.8M | 69.4M | 163.6M |
| Short-term investments | 642.0M | 436.4M | 250.2M | 302.0M | 373.3M | 305.9M | 507.7M | 338.8M | 271.9M | 365.4M |
| Receivables | 121.5M | 98.7M | 98.3M | 62.2M | 64.4M | 48.2M | 35.8M | 26.1M | 17.3M | 5.90M |
| Inventory | 111.4M | 91.7M | 40.4M | 11.6M | 14.1M | 9.68M | 6.34M | 4.07M | 5.25M | 4.17M |
| Current assets | 1.06B | 938.3M | 616.1M | 507.9M | 617.8M | 717.6M | 760.3M | 526.1M | 373.5M | 547.9M |
| Property, plant and equipment | 7.51M | 4.21M | 4.61M | 6.02M | 8.05M | 9.16M | 3.18M | 3.31M | 2.66M | 3.08M |
| Goodwill | 1 | 0 | 0 | |||||||
| Total assets | 1.56B | 1.19B | 749.0M | 587.8M | 700.1M | 782.6M | 783.2M | 540.2M | 384.5M | 561.2M |
| Accounts payable | 10.9M | 16.2M | 17.5M | 12.7M | 6.88M | 8.49M | 7.22M | 3.17M | 8.79M | 3.91M |
| Current liabilities | 277.1M | 394.9M | 254.3M | 125.6M | 96.1M | 106.0M | 74.8M | 59.6M | 49.0M | 42.6M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 52.2M | 52.0M | 57.2M | 62.0M | 64.4M | 49.5M | 9.79M | |||
| Total liabilities | 336.8M | 455.0M | 317.2M | 187.4M | 159.2M | 155.6M | 84.0M | 61.1M | 49.2M | 42.7M |
| Shareholders' equity | 1.23B | 732.8M | 431.8M | 400.4M | 540.9M | 627.0M | 699.1M | 479.1M | 335.3M | 518.4M |
| Shares outstanding | 170.3M | 166.7M | 164.7M | 162.1M | 161.0M | 159.6M | 155.3M | 143.9M | 124.4M | 121.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 109.8M | 157.7M | 16.7M | -114.0M | -125.7M | -136.2M | -151.1M | -167.5M | -217.8M | -208.4M |
| Capital spending | -4.69M | -523.0K | -50.0K | 0 | -1.12M | -7.59M | -1.13M | -2.10M | -812.0K | -1.51M |
| Free cash flow | 105.1M | 157.2M | 16.7M | -114.0M | -126.8M | -143.8M | -152.3M | -169.6M | -218.6M | -209.9M |
| Cash from investing | -302.6M | -30.5M | 32.0M | 73.2M | -71.1M | 192.5M | -165.8M | -71.5M | 92.5M | -261.9M |
| Cash from financing | 49.9M | 6.84M | 25.1M | 8.20M | 18.2M | 81.0M | 371.8M | 306.6M | 31.2M | 533.8M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 18.2M | 81.0M | 371.8M | 306.6M | 31.2M | 518.9M | ||||
| Change in cash | -142.8M | 133.9M | 73.8M | -32.6M | -178.6M | 137.3M | 54.9M | 67.7M | -94.1M | 63.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 23, 2026 | Management or board change | SEC |
| 8-K · Current report | Sep 24, 2026 | Current report | SEC |
| 8-K · Current report | Sep 11, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 5, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jun 10, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 8-K · Current report | May 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 26, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 30, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 26, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 25, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 8-K · Current report | Nov 3, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 8-K · Current report | Jun 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 29, 2025 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 27, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 21, 2025 | Other filings | SEC |
| 8-K · Current report | May 20, 2025 | Material contract | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 16, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 14, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 9, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 16, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 6, 2025 | Other filings | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 11, 2024 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 23, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 23, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 8-K · Current report | May 29, 2024 | Management or board change | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | May 29, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Apr 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 11, 2024 | Current report | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 10-K · Annual report | Feb 27, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 30, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2023 | Other filings | SEC |
| 4 · Change in ownership | Nov 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from ACADIA Pharmaceuticals Inc.’s releases · as of Oct 28, 2026
- Common shares
- 172,828,972
- Fully diluted
- 172,828,972
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 172,828,972 | Oct 28, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 28, 2026 | 172,828,972 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Laura Brege Other companies: Edgewise Therapeutics, Inc. (Director · Since at least Mar 25, 2021); Mirum Pharmaceuticals, Inc. (Board Member · Since at least Jul 17, 2019); Pacira BioSciences, Inc. (Director · Since at least Jun 6, 2016); Aratana Therapeutics Inc (Director · Jun 24, 2016 – Jul 27, 2018 · Past); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); Dynavax Technologies Corporation (Director · May 31, 2016 – May 30, 2019 · Past) | Director · Since at least Jun 10, 2016 |
| Elena Ridloff Other companies: Immunic, Inc. (Director · Since at least Aug 6, 2026); Sionna Therapeutics, Inc. (CFO and CBO · Since at least Feb 6, 2025); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Kronos Bio Inc (Director · Since at least Oct 8, 2020) | EVP and CFO · Jan 6, 2021 – Apr 29, 2021 · Past |
| James Daly Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Oct 1, 2026); Cytokinetics, Incorporated (Director · Since at least Aug 19, 2025); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 20, 2025) | Director · Since at least May 29, 2025 |
| Michael Yang Other companies: Ionis Pharmaceuticals, Inc. (Director · Since at least Dec 14, 2023); Pacira BioSciences, Inc. (Director · Since at least Oct 6, 2023); Akcea Therapeutics Inc (Director · Sep 20, 2019 – Oct 12, 2020 · Past) | EVP and CCO · Apr 18, 2018 – Jan 6, 2021 · Past |
| Douglas J. Williamson Other companies: Vistagen Therapeutics, Inc. (Director · Since at least Jul 29, 2026); Avadel Pharmaceuticals PLC (Chief Medical Officer · Feb 14, 2022 – Feb 14, 2022 · Past) | Executive VP, Research & Dev · Feb 1, 2023 – Feb 10, 2023 · Past |
| Elizabeth H Z Thompson Other companies: IGM Biosciences Inc (Director · Since at least Oct 3, 2023) | EVP, Head of Research & Dev · Since at least Apr 4, 2024 |
| Jonathan M. Poole Other companies: Evelo Biosciences, Inc. (CFO · May 8, 2018 – Jan 28, 2020 · Past) | Director · Since at least Mar 3, 2026 |
| Thomas Garner Other companies: Lexicon Pharmaceuticals, Inc. (SVP, Chief Commercial Officer · Oct 9, 2023 – Feb 8, 2024 · Past) | EVP, Chief Commercial Officer · Since at least Dec 9, 2024 |
| Adora Ndu | Director · Since at least May 29, 2026 |
| Carl Segerstrom | Chief People Officer · Since at least Jul 6, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Catherine Owen Adams | Chief Executive Officer · Since at least Sep 28, 2026 |
| Edmund Harrigan | Director · Since at least Jun 1, 2026 |
| Elizabeth Garofalo | Director · Since at least Jun 1, 2026 |
| Glenn Baity | EVP AND GC · Oct 4, 2017 – Apr 18, 2018 · Past |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER · Since at least Jun 23, 2020 |
| Jennifer J. Rhodes | Chief Legal Officer and Secretary · Since at least Nov 4, 2026 |
| Julian Baker | Director · Since at least Nov 5, 2026 |
| Konstantina Katcheves | Chief Business and Strategy Officer · Since at least Nov 5, 2025 |
| Mark Schneyer | EVP, CHIEF FINANCIAL OFFICER · Since at least Apr 5, 2025 |
| Scott Cenci | Chief Information and Data Officer · Since at least Aug 4, 2025 |
| Stephen Biggar | Chairman · Since at least Mar 3, 2026 |
Log in to ask 6ix AI your own questions about ACADIA Pharmaceuticals Inc.